JP2022527373A5 - - Google Patents

Info

Publication number
JP2022527373A5
JP2022527373A5 JP2021559435A JP2021559435A JP2022527373A5 JP 2022527373 A5 JP2022527373 A5 JP 2022527373A5 JP 2021559435 A JP2021559435 A JP 2021559435A JP 2021559435 A JP2021559435 A JP 2021559435A JP 2022527373 A5 JP2022527373 A5 JP 2022527373A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
sequence described
lcdr1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021559435A
Other languages
English (en)
Japanese (ja)
Other versions
JP7511576B2 (ja
JP2022527373A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/027554 external-priority patent/WO2020210551A1/en
Publication of JP2022527373A publication Critical patent/JP2022527373A/ja
Publication of JP2022527373A5 publication Critical patent/JP2022527373A5/ja
Priority to JP2024002528A priority Critical patent/JP7688175B2/ja
Application granted granted Critical
Publication of JP7511576B2 publication Critical patent/JP7511576B2/ja
Priority to JP2025085725A priority patent/JP7904951B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021559435A 2019-04-10 2020-04-09 Retを結合するヒト抗体およびその使用方法 Active JP7511576B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024002528A JP7688175B2 (ja) 2019-04-10 2024-01-11 Retを結合するヒト抗体およびその使用方法
JP2025085725A JP7904951B2 (ja) 2019-04-10 2025-05-22 Retを結合するヒト抗体およびその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962832218P 2019-04-10 2019-04-10
US62/832,218 2019-04-10
PCT/US2020/027554 WO2020210551A1 (en) 2019-04-10 2020-04-09 Human antibodies that bind ret and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024002528A Division JP7688175B2 (ja) 2019-04-10 2024-01-11 Retを結合するヒト抗体およびその使用方法

Publications (3)

Publication Number Publication Date
JP2022527373A JP2022527373A (ja) 2022-06-01
JP2022527373A5 true JP2022527373A5 (cg-RX-API-DMAC7.html) 2023-01-10
JP7511576B2 JP7511576B2 (ja) 2024-07-05

Family

ID=70554175

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021559435A Active JP7511576B2 (ja) 2019-04-10 2020-04-09 Retを結合するヒト抗体およびその使用方法
JP2024002528A Active JP7688175B2 (ja) 2019-04-10 2024-01-11 Retを結合するヒト抗体およびその使用方法
JP2025085725A Active JP7904951B2 (ja) 2019-04-10 2025-05-22 Retを結合するヒト抗体およびその使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024002528A Active JP7688175B2 (ja) 2019-04-10 2024-01-11 Retを結合するヒト抗体およびその使用方法
JP2025085725A Active JP7904951B2 (ja) 2019-04-10 2025-05-22 Retを結合するヒト抗体およびその使用方法

Country Status (11)

Country Link
US (1) US20220185900A1 (cg-RX-API-DMAC7.html)
EP (1) EP3953390A1 (cg-RX-API-DMAC7.html)
JP (3) JP7511576B2 (cg-RX-API-DMAC7.html)
KR (2) KR102967743B1 (cg-RX-API-DMAC7.html)
CN (1) CN113993898B (cg-RX-API-DMAC7.html)
AU (1) AU2020270966B2 (cg-RX-API-DMAC7.html)
CA (1) CA3134258A1 (cg-RX-API-DMAC7.html)
IL (1) IL287067A (cg-RX-API-DMAC7.html)
MA (1) MA55615A (cg-RX-API-DMAC7.html)
MX (1) MX2021012335A (cg-RX-API-DMAC7.html)
WO (1) WO2020210551A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4277904A1 (en) 2021-01-15 2023-11-22 Seagen Inc. Immunomodulatory antibody-drug conjugates
MX2023009113A (es) 2021-02-03 2023-08-10 Seagen Inc Conjugados y compuestos inmunoestimulantes.
WO2023144790A1 (en) * 2022-01-31 2023-08-03 Glaxosmithkline Intellectual Property (No.3) Limited Prevention and treatment of headaches
EP4518905A1 (en) 2022-05-06 2025-03-12 Seagen Inc. Immunomodulatory antibody-drug conjugates
IL318450A (en) 2022-08-03 2025-03-01 Seagen Inc Immunostimulatory ANTI-PD-L1-Drug conjugates
EP4321522A1 (en) 2022-08-12 2024-02-14 Seagen Inc. Cytotoxic compounds and conjugates thereof
AU2024403267A1 (en) * 2023-12-20 2026-07-16 Dianthus Therapeutics Opco, Inc. Pharmaceutical compositions comprising antibodies for treatment of c1s mediated disorders and methods of using the same

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6677135B1 (en) 1996-05-08 2004-01-13 Biogen, Inc. Ret ligand (RetL) for stimulating neutral and renal growth
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
JP2008546716A (ja) * 2005-06-17 2008-12-25 バイオジェン・アイデック・エムエイ・インコーポレイテッド 抗GFRα3抗体
JPWO2007049624A1 (ja) * 2005-10-24 2009-04-30 武田薬品工業株式会社 癌の予防・治療剤
ATE537190T1 (de) 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
ES2701649T3 (es) 2009-01-14 2019-02-25 Ablynx Nv Administración pulmonar de dominios variables individuales de inmunoglobulina y constructos de los mismos
CN102459332B (zh) 2009-06-05 2015-08-19 埃博灵克斯股份有限公司 用于预防和/或治疗呼吸道感染的单价、二价和三价抗人呼吸道合胞病毒(hrsv)纳米抗体构建体
TWI507525B (zh) 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
JO3462B1 (ar) * 2012-08-22 2020-07-05 Regeneron Pharma أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها
KR102288722B1 (ko) * 2013-08-30 2021-08-12 모멘티브 퍼포먼스 머티리얼즈 인크. 아미노산을 갖는 수분 경화성 화합물
GB201512215D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
AU2016332900C1 (en) 2015-09-29 2024-07-04 Amgen Inc. ASGR inhibitors
KR101859576B1 (ko) * 2016-06-30 2018-05-18 가톨릭대학교 산학협력단 Kif5b-ret 융합 단백질을 특이적으로 검출하는 항체 및 이의 용도
KR20200059243A (ko) 2017-09-20 2020-05-28 리제너론 파마슈티칼스 인코포레이티드 패신저 유전자 돌연변이 부담이 높은 종양을 가진 환자에 대한 면역 치료요법

Similar Documents

Publication Publication Date Title
Zhang et al. The role of interleukin-17 in inflammation-related cancers
Zhong et al. A novel IL6 antibody sensitizes multiple tumor types to chemotherapy including trastuzumab-resistant tumors
AU2022246477A1 (en) Therapy involving antibodies against claudin 18.2 for treatment of cancer
EP3894013A1 (en) Method of treating cancer with an immune checkpoint inhibitor in combination with another therapeutic agent
JP2024028805A (ja) がん処置のための坑il-8抗体及び坑pd-1抗体を用いる組合せ治療
CN114761013A (zh) 治疗骨髓纤维化和相关病症的方法
US20230088070A1 (en) Use of il-1beta binding antibodies
JP2015514113A (ja) 単一特異性および二重特異性抗igf−1rおよび抗erbb3抗体の用法および用量
Schinzari et al. Targeted therapy in advanced gastric carcinoma: the future is beginning
US20250092127A1 (en) IL-4/IL-13 Pathway Inhibitors for Enhanced Efficacy in Treating Cancer
US20230101029A1 (en) Methods of using il-33 protein in treating cancers
Duong et al. T cell Immunoglobulin and mucin domain containing protein 3 (TIM-3) inhibitors in oncology clinical trials: a review
JP2024038034A (ja) 膀胱癌の抗pd-l1抗体治療
JP2019527697A5 (cg-RX-API-DMAC7.html)
JP2020510673A (ja) がんの治療のための低分子csf−1r阻害剤とcd40に特異的に結合するアゴニスト抗体とを含む併用療法
JP7341130B2 (ja) 癌を治療するための組成物および治療方法
Wu et al. Next‐Generation HER‐2 Tumor‐Targeted Delivery of the STING Agonist Immune‐Stimulating Antibody Conjugate (ISAC) Improves Anticancer Efficacy and Induces Immunological Memory
US20160324962A1 (en) Compositions and methods for treating sarcoma
RU2021129250A (ru) Человеческие антитела, связывающие ret, и способы их применения
Donzelli et al. Managing Treatment‐Emergent Immune Effector Cell‐Associated Hemophagocytic Lymphohistiocytosis‐Like Syndrome Following CAR‐T Cell Therapy: A Case‐Based Review of the use of Emapalumab
Al-Batran et al. Recent advances and future trends in the targeted therapy of metastatic gastric cancer
EP3164154A1 (en) Combination therapy
JP2023511277A (ja) Ccr5陽性の転移性のがんの処置のためのccr5結合剤
US20220089740A1 (en) Tim-3 antibodies and combinations with other checkpoint inhibitors for the treatment of cancer
Garrido et al. The anti-tumor activity of the 7A7 antibody, specific to murine EGFR, is independent of target expression levels in immunocompetent mice